Longevity & Anti-Aging
Thymalin
Mechanism & research context
Thymic peptide complex with limited Eastern European clinical reports in elderly and immunocompromised populations.
Origin: Thymic peptide bioregulator extracted from calf thymus.
Safety flags
0 flagsNo curator-recorded safety flags for this entry. Absence of recorded flags is not evidence of safety. Many peptides lack adequate human data.
Research papers
16 recordsCitation links route to PubMed, Europe PMC, and PMC. Presence of a study is not endorsement. Records are refreshed from PubMed on a regular cadence; rows marked “Live search link” will resolve to a current PubMed search until a full citation has been ingested.
-
· 2026 Open access
Targeting Leukopoiesis: Pharmacological and Biotechnological Strategies for the Treatment of Leukopenia.
-
· 2025 Open access
Immunotherapy for tuberculosis: current strategies and future directions.
-
· 2024
Reparative osteogenesis in mandible in cases of filling a bone defect with hydroxyapatite-containing osteotropic material and injecting the surrounding soft tissues with thymalin: experimental and morphological study.
-
· 2024
Expression features of T-lymphocytes, B-lymphocytes and macrophages in the post-traumatic regenerate of the mandible rats under conditions of filling a bone defect with hydroxyapatite-containing osteotropic material and thymalin injecting the surrounding soft tissues.
-
· 2023 Open access
The Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19.
-
· 2022 Open access
Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line.
-
· 2022
[Morphological compound and indicators of the blood clotting system in severe COVID-19 patients of middle aged and elderly during treatment of Tocilizumab and Thymalin.]
-
· 2021 Open access
The Use of Thymalin for Immunocorrection and Molecular Aspects of Biological Activity
-
· 2021 Open access
Peptide Drug Thymalin Regulates Immune Status in Severe COVID-19 Older Patients
-
· 2021
Esophageal Cancer: 10-Year Survival After Surgery
-
· 2021 Open access
Results and Prospects of Using Activator of Hematopoietic Stem Cell Differentiation in Complex Therapy for Patients with COVID-19.
-
· 2020 Open access
Peptides: Prospects for Use in the Treatment of COVID-19.
-
· 2020 Open access
Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells.
-
· 2019
[TREATMENT OF SECRETORY OTITIS MEDIA IN CHILDREN, DEPENDING ON THE STAGE OF THE PROCESS AND ON THE BACKGROUND OF THE PATHOLOGICAL CONDITIONS].
-
· 2018
Effect of Thymalin on the Tumor and Thymus under Conditions of Activation Therapy In Vivo.
-
Review · PubMed (NCBI) Live search link
PubMed literature search: Thymalin
Run importer to populate live PubMed records. This placeholder links to a live search.
Clinical trials
1 record-
Live search Live search
Live ClinicalTrials.gov search: Thymalin
Condition: See live results
Open on ClinicalTrials.gov ↗
Doses reported in studies
0 recordsNo study-protocol dose records have been curated for Thymalin yet. Absence of records is not evidence of safety — many peptides lack adequate human-trial data in the first place.
Records here are populated from public sources only (ClinicalTrials.gov protocol summaries and FDA-approved labels) and must cite a verifiable source URL. They are not added from forum posts, vendor pages, anecdotal write-ups, or social media.
These entries describe what was studied. They do not tell you what to take, how to reconstitute anything, how to fill a capsule, how often to administer, or where to obtain a compound. If you are considering use of Thymalin, those decisions belong with a licensed clinician working from the full label or trial record — not from this summary.
Why this page does not list a dose for self-use
The "Doses reported in studies" section above (when populated) describes what was administered in a cited study or label, under medical supervision, in a specific population. It is not a dosing guide for self-use. Separately, we do not publish anecdotal or community-reported dose ranges, administration methods, vial concentrations, or capsule masses for Thymalin. Anecdotal figures for unapproved compounds are not harm-reduction data: they lack denominators for adverse events, cannot account for individual physiology or compound purity, and normalise unsupervised use. See the safety policy for the full reasoning.
If this compound has an FDA-approved label
If a label exists, the regulator-reviewed dosing and administration information is there — read it in the context of a prescriber's evaluation.
Questions worth bringing to a clinician
- What is the evidence for this compound in someone with my history?
- What are the realistic, regulator-reviewed alternatives?
- What would you monitor, and what would make you stop?
If you have already taken a peptide and feel unwell: contact emergency services. In the United States, Poison Control is reachable 24/7 at 1-800-222-1222. Do not wait for a community thread.